GlassScriptPhysician profile
Harold A Horowitz
NPI 1134183239
$4,126.43
in general payments reported to CMS, 2019-2025
22 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $97.22 · 2021: $98.38 · 2022: $307 · 2023: $195 · 2024: $2,396 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607 · Travel and Lodging: $1,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.31 |
| Travel and Lodging | $1,339.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $2,070.03 | 2024 | |
| Horizon Therapeutics Plc | $293.59 | 2019-2023 | Krystexxa |
| Organogenesis INC. | $248.15 | 2022-2025 | Affinity |
| Gilead Sciences, INC. | $170.79 | 2019-2024 | |
| Smith+Nephew, INC. | $161.88 | 2019-2022 | |
| Advanced Oxygen Therapy INC. | $152.45 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $142.61 | 2019-2022 | |
| Amgen INC. | $125.00 | 2024 | |
| Sanofi-Aventis U.S. LLC | $124.99 | 2025 | |
| Medtronic, INC. | $105.43 | 2022 | |
| Abbvie INC. | $98.38 | 2021 | |
| Acera Surgical, INC. | $95.35 | 2023 | Restrata Wound Matrix |
| Averitas Pharma INC. | $60.17 | 2024 | Qutenza |
| Merck Sharp & Dohme LLC | $43.41 | 2019-2024 | Delstrigo, Pifeltro, Dificid |
| Paratek Pharmaceuticals, INC. | $41.04 | 2025 | Nuzyra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $35.06 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $33.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.29 | 2024 | |
| Lilly USA, LLC | $29.07 | 2025 | Zepbound, Mounjaro |
| Dexcom, INC. | $28.93 | 2024 | Dexcom G7 Gss (161) |
| Insulet Corporation | $22.09 | 2024 | Omnipod |
| Bioventus LLC | $15.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Horowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.